Article Text

Download PDFPDF

Response to: ‘Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland’ by Quills et al
Free
  1. Jasvinder A Singh1,2
  1. 1Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
  2. 2Medicine Service, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
  1. Correspondence to Dr Jasvinder A Singh, University of Alabama at Birmingham, Birmingham, AL 35294, USA; jasvinder.md{at}gmail.com

Statistics from Altmetric.com

We appreciate the interest and comments by Quilis et al1 on our recent publication.2 Quilis et al draw our attention to the incidence of cutaneous adverse reactions (CARs) with febuxostat in people who had already had reactions with allopurinol. In their study which included several practices in Spain from 2011 to 2018, 15% of people developed these reactions with febuxostat1 compared with the 9%–15% range reported previously for similar patient populations from the USA and France.3 4 CARs are frequent, and are associated with significant morbidity.5 Interestingly, the rate of CARs in people newly starting febuxostat and not previously …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles